Clinical Trial: A Bioequivalence Study of Dasatinib Tablet
Study Status: Completed
Recruit Status: Completed
Condition: Leukemia, Myelogenous, Chronic
Study Type: Interventional
Official Title: A Bioequivalence Study Between the Generic Dasatinib Tablet and Reference Product in Vivo
Brief Summary:
This is a clinical study to evaluate the bioequivalence of dasatinib tablet produced by Chia Tai Tianqing Pharmaceutical Group Co., Ltd. and Sprycel® produced by Bristol Myers Squibb after single dose in healthy subjects, so as to provide reference for clinical evaluation and clinical medication; to observe the safety of the dasatinib tablet and the reference drug Sprycel® in healthy subjects under fasting and fed states.
Read more